Navigation Links
VIRxSYS Presents Data on HIV Vaccine at Keystone HIV Vaccine Symposia
Date:3/28/2008

HIV-Based Lentiviral vector VRX1023 Shows Promising Results

GAITHERSBURG, Md., March 28 /PRNewswire/ -- VIRxSYS Corporation will present initial scientific data for VRX1023 today at the Keystone Symposia Conference in Banff, Alberta. VRX1023 is part of a new vaccine approach -- using HIV-based lentivector as vector boost. VRX1023, an HIV antigen expressing lentiviral vector, has produced positive results in mice and in preliminary non-human primate studies. A larger, confirmatory study in Rhesus Macaques has been initiated.

"VRX1023 shows exciting promise," says Dr. Franck Lemiale, Director of Research and Development, Immunobiology for VIRxSYS. "The results from these mouse studies are very encouraging. We have seen significant long term response against HIV proteins both in terms of cellular immunity, which is mediated by T Lymphocytes, and humoral immunity, which is mediated by antibodies."

VIRxSYS takes a different approach as anti-HIV vaccine than recently publicized failed vaccines. The company is using an engineered HIV-based lentiviral vector to deliver the vaccinating antigens. In small animals, the VRX1023 lentivector has induced long-lasting cellular and humoral response against HIV. Using a DNA prime/vector boost strategy, VIRxSYS has obtained with VRX1023 greater anti-HIV immune responses than with other viral vector boost approaches currently used in the clinic, including adenoviral vectors similar to those that have been extensively tested in patients.

The ultimate goal for an anti-HIV vaccine is to suppress the impact of the initial infection, thereby significantly slowing the process of the disease. Due to the properties of the virus, a traditional total sterilizing goal may not be achievable for an anti-HIV vaccine. The next step would be to a prophylactic vaccine, which would reduce the impact of hyper-viremia in the first weeks of the infection. The aim of this vaccine is to suppress initial viremia, prevent
'/>"/>

SOURCE VIRxSYS
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
2. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
3. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
4. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
5. CEL-SCI Presents Data for CEL-1000 as a Vaccine Adjuvant with Recombinant Hepatitis B Virus Protein
6. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
7. Targanta Presents First Data Demonstrating In Vitro Activity and In Vivo Efficacy of Prodrugs in Osteomyelitis Models
8. Wyeth Presents Phase 3 Fracture Data for Bazedoxifene, an Investigational Therapy for Osteoporosis
9. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
10. Surface Logix Presents Positive Phase 1 Repeat-Dose Trial Data on SLx-4090 at The 16th International Symposium on Drugs Affecting Lipid Metabolism
11. Wyeth Presents New Phase 3 Data and Updates Regulatory Timing for NDA Filing of Bazedoxifene/Conjugated Estrogens
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... BOSTON , Jan. 15, 2014 Tegra Medical is ... Mark King as its new Chief Executive Officer.  Mark ... in which he has overseen the company,s four facilities in ... and Costa Rica.  Mr. King joined Tegra Medical in 2012 ...
(Date:1/15/2014)...  According to Millennium Research Group (MRG), the global ... the United States and European transcatheter ... moderately through 2022, with embolization particles representing one ... in drug-eluting beads (DEBs) and radioembolization spheres in ...
(Date:1/15/2014)... Jan. 15, 2014 Reportlinker.com announces that ... in its catalogue: ... Delivery Systems -- Focus on End Users ... STUDY OBJECTIVES A drug delivery ...
Breaking Medicine Technology:Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18
... Bermuda, Dec. 16 Celtic Pharmaceutical Holdings L.P. ("Celtic ... preliminary analyses completed on the two double-blinded studies of XERECEPT ... edema, as well as an initial database lock on the ... , The results of these studies ...
... Live Broadcast on December 18, 2008 at 9 a.m. Eastern Time ... MannKind Corporation (Nasdaq: MNKD ) will host ... 3 studies of AFRESA(TM), the company,s ultra rapid acting, inhaled insulin product, ... , , To participate in the live ...
Cached Medicine Technology:Celtic Pharma Announces Update on Status of XERECEPT(R) Program Sale Planned in 2009 2MannKind Corporation to Review Positive Results From Final Two Pivotal Phase 3 Clinical Studies in Type 1 and Type 2 Diabetes 2
(Date:4/18/2014)... of Medicine researchers have been awarded two-year grants for ... announced this month. Of the 110 initial submissions to ... Forum Program, only four projects were funded, three of ... Jonathan Powell, M.D., Ph.D.; G. William Wong, Ph.D.; and ... professor of oncology, will use his $500,000 proof of ...
(Date:4/18/2014)... in French . ... and regenerative medicine. A team led by Ludwik Leibler ... Tech) and Didier Letourneur from the Laboratoire Recherche Vasculaire ... demonstrated that the principle of adhesion by aqueous solutions ... soft-tissue organs and tissues. This easy-to-use gluing method has ...
(Date:4/17/2014)... pain relief targets that could be used to ... King,s College London made the discovery when researching ... of the body. , Dr Marzia Malcangio said: ... pain generation and our findings could help chemotherapy ... One potential side effect of some chemotherapy drugs ...
(Date:4/17/2014)... (April 17, 2014) Two recent papers by ... and colleagues may help scientists develop treatments or ... fever, Japanese encephalitis and other disease-causing flaviviruses. , ... and molecular genetics at the School of Medicine ... Hughes Medical Institute, and colleagues recently published articles ...
(Date:4/17/2014)... who treat patients with a severe and progressive ... agonizing treatment decision. , The drug sirolimus can ... shortness of breath. But some patients eventually may ... fatal complications following transplantation. , "It,s a terrible ... of Loyola University Medical Center,s LAM Clinic and ...
Breaking Medicine News(10 mins):Health News:Innovative strategy to facilitate organ repair 2Health News:Innovative strategy to facilitate organ repair 3Health News:New pain relief targets discovered 2Health News:CU researchers discover target for treating dengue fever 2Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3
... 21 BET News correspondent, Andre Showell will lead the discussion during ... Wednesday, July 22 ( ) at 8 ... broadcast of the entire news conference along with pre and post analysis ... The President is expected to discuss health care legislation and ...
... LOUIS, July 21 Young Innovations, Inc. (Nasdaq: YDNT ) ... $0.04 per share, payable September 15, 2009 to all shareholders of record ... of up to 500,000 shares of the Company,s stock. This authorization, which ... scheduled to expire on July 31, 2009. , , ...
... , , FRANKLIN, Tenn., July 21 ... documentation technology and services, today announced details for the release of its ... , Spheris plans to issue its earnings ... trading on Thursday, August 6, 2009, and will host a conference call ...
... , , HOUSTON, July 21 ... of fiscal 2009 on Thursday, August 6, 2009. , , ... at 11 a.m. ET following distribution of the earnings release. Additional information will ... the News Room on the day of the earnings announcement. , ...
... Ill., July 21 Since 2003, the University HealthSystem Consortium (UHC) has ... the sixth consecutive year. The Honor Roll publicly recognizes and celebrates all ... , All Honor Roll recipients must exhibit 10 ... a work environment founded on dignity and respect for all employees , ...
... MEQUON, Wis., July 21 Wonderbox Technologies has ... to benefit from continued advances in technology and software features. ... designed for managed care benefit administration and case management. The ... scheduling, managing, and monitoring day-to-day care tasks and case assignments. ...
Cached Medicine News:Health News:BET Networks Airs Special Coverage of President Obama's News Conference on Health Care 2Health News:Young Innovations, Inc. Board of Directors Declares Quarterly Dividend and Authorizes Share Repurchase Program 2Health News:Spheris Sets Second Quarter 2009 Earnings Release and Conference Call Dates 2Health News:US Oncology to Report 2009 Second Quarter Operating Results 2Health News:University HealthSystem Consortium Recognized as a Company That Cares for Sixth Year in a Row 2Health News:Wonderbox Technologies(R) Releases Version 4.5 of the Enterprise System 2
Coude Foley Catheters (Latex) 2-Way Amber...
Silicone Elastomer-Coated Latex Foley Catheters 3-Way...
Silicone Foley Catheters 3-Way...
Midstream Catch Kits...
Medicine Products: